trending Market Intelligence /marketintelligence/en/news-insights/trending/gntbzcy0xkuqydxihdjcsq2 content esgSubNav
In This List

Imugene closes A$8.1M rights issue

Blog

Baird Research is Now Exclusively Available in S&P Global’s Aftermarket Research Collection

Blog

Japan M&A By the Numbers: Q4 2023

Blog

Essential IR Insights Newsletter Fall - 2023

Case Study

A Corporation Clearly Pinpoints Activist Investor Activity


Imugene closes A$8.1M rights issue

Australia's Imugene Ltd. closed a previously announced fully underwritten 1-for-9.5 rights issue.

Shareholders subscribed for 139,713,059 shares at 2.7 Australian cents each. The cancer drug developer raised about A$3.8 million.

The resulting shortfall of 160,803,118 shares will be allocated to institutional investors.

The company expects to complete the issue of shares and attaching options under the rights issue July 11.

Imugene develops immunotherapies for gastric and breast cancer.